Objective: The UKPDS 34 and 51 showed that intensive blood glucose control with metformin is cost-saving and increases life expectancy in overweight type 2 diabetic patients in the United Kingdom. Diabetes is becoming an important health problem in urban China. This study addresses the effects and costs of intensive blood glucose control in this setting, aimed at supporting decision-making on the allocation of scarce resources. - Methods: A decision analytic model was developed to estimate the costs and effectiveness of intensive blood glucose control in overweight type 2 diabetes patients in Beijing, compared with usual care in accordance with clinical practice. The analysis was carried out from a health-care perspective. - Results: The ba...
OBJECTIVE:To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE...
BackgroundNational guidance on preventing type 2 diabetes mellitus (T2DM) in the UK recommends low-i...
Objective: The UKPDS 34 and 51 showed that intensive blood glucose control with metformin is cost-sa...
Aims/hypothesis. to estimate the economic efficiency of intensive blood-glucose control with metform...
AIMS/HYPOTHESIS: This study estimated the economic efficiency (1) of intensive blood glucose control...
Background and objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the d...
Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) t...
Background: The Diabetes Impact Study followed up a large national population-based screening study ...
<div><h3>Background</h3><p>The Diabetes Impact Study followed up a large national population-based s...
BACKGROUND: In Singapore, as diabetes is an increasingly important public health issue, the cost-eff...
AbstractObjectivesTo evaluate the long-term cost-effectiveness of switching from insulin glargine (I...
Objectives: To estimate the direct and indirect costs of type 2 diabetes mellitus (T2DM) in China in...
Background: In Singapore, as diabetes is an increasingly important public health issue, the cost-eff...
OBJECTIVE: To estimate the cost effectiveness of conventional versus intensive blood glucose control...
OBJECTIVE:To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE...
BackgroundNational guidance on preventing type 2 diabetes mellitus (T2DM) in the UK recommends low-i...
Objective: The UKPDS 34 and 51 showed that intensive blood glucose control with metformin is cost-sa...
Aims/hypothesis. to estimate the economic efficiency of intensive blood-glucose control with metform...
AIMS/HYPOTHESIS: This study estimated the economic efficiency (1) of intensive blood glucose control...
Background and objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the d...
Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) t...
Background: The Diabetes Impact Study followed up a large national population-based screening study ...
<div><h3>Background</h3><p>The Diabetes Impact Study followed up a large national population-based s...
BACKGROUND: In Singapore, as diabetes is an increasingly important public health issue, the cost-eff...
AbstractObjectivesTo evaluate the long-term cost-effectiveness of switching from insulin glargine (I...
Objectives: To estimate the direct and indirect costs of type 2 diabetes mellitus (T2DM) in China in...
Background: In Singapore, as diabetes is an increasingly important public health issue, the cost-eff...
OBJECTIVE: To estimate the cost effectiveness of conventional versus intensive blood glucose control...
OBJECTIVE:To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE...
BackgroundNational guidance on preventing type 2 diabetes mellitus (T2DM) in the UK recommends low-i...